📍Recalling firmQuVa Pharma, Inc.1075 W Park One Dr Ste 100 · Sugar Land, TX 77478-2576
✎ GovInfoNow plain-language explainer
QuVa Pharma, Inc. is recalling one lot of oxyTOCIN 30 Units/500 mL added to 0.9% Sodium Chloride Injection for IV Use. The recall was issued because the product is subpotent and did not contain the active drug. This affects 648 bags distributed nationwide in the USA. Read more at govinfonow.com/recall/37093-quva-pharma-recalls-oxytocin-iv-bags-due-to-subpotency.
“QuVa Pharma Recalls Oxytocin IV Bags Due to Subpotency.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/37093-quva-pharma-recalls-oxytocin-iv-bags-due-to-subpotency. Based on FDA recall #D-1302-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1302-2020%22&limit=1).
The FDA announced on May 28, 2020, that QuVa Pharma, Inc. voluntarily recalled oxyTOCIN added to 0.9% Sodium Chloride Injection for failing potency specifications. The subpotent drug may not contain the expected amount of active ingredient.
How to tell if you have it
Brand: QuVa Pharma
Product: oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV Use, Rx only
NDC: 70092-1068-07
Lot#: 30010515
Quantity: 648 bags
The hazard
The product is classified as a subpotent drug because it did not contain the required drug potency. The FDA classified this recall as Class II.
Context
GovInfoNow's records show QuVa Pharma, Inc. has had 9 other recalls on record since March 30, 2016. Recent brand recalls include a June 24, 2026, recall of Methohexital Sodium due to impurity failures and an Oct. 10, 2025, recall of R.E.C.K. Injection due to particulate matter. Other recent recalls of similar products include a Jan. 16, 2026, Specialty Process Labs Thyroid Product Recall for subpotent drug risk and Nov. 26, 2025, Somerset Therapeutics Cisatracurium Besylate Injection Recalls for subpotent product risks.
How to tell if you have this one
Check for oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride Injection for IV Use. The specific lot number is 30010515, and the NDC is 70092-1068-07. The product was distributed nationwide in the USA.
Brand
QuVa Pharma
Category
Drug
Based on the official FDA remedy
What to do — step by step
Stop using the product
Do not administer or use any bags from lot 30010515 due to the subpotent hazard.
Contact manufacturer
Call QuVa Pharma at 888-339-0874 for further instructions regarding the recall.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 20 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1302-2020 (May 28, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1302-2020 to see it in context.
Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.